A disintegrin and metalloproteinase domain 17 regulates colorectal cancer stem cells and chemosensitivity via Notch1 signaling

Stem Cells Translational Medicine

Volumn 5, Issue 3, 2016, Pages 331-338

  Wang, Rui ^a   Ye, Xiangcang ^a   Bhattacharya, Rajat ^a   Boulbes, Delphine R ^a   Fan, Fan ^a   Xia, Ling ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

A disintegrin and metalloproteinase domain 17; Cancer stem cells; Chemosensitivity; Colorectal cancer; Jagged 1; Notch1

Indexed keywords

ADAM PROTEIN; FLUOROURACIL; NOTCH1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM17 PROTEIN, HUMAN; HYDROXAMIC ACID; NOTCH1 PROTEIN, HUMAN; TAPI-2;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CELL VIABILITY ASSAY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; HUMAN; HUMAN CELL; MTT ASSAY; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ADAM PROTEINS; ADAM17 PROTEIN; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; NEOPLASTIC STEM CELLS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION;

EID: 84959342608     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0168     Document Type: Article

References (41)

1. Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol 2015; 33: 1809-1824.
2. Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013; 8: 83-96.
3. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin Oncol 2011; 38: 552-560.
4. Flemming A. Cancer stem cells: Targeting the root of cancer relapse. Nat Rev Drug Discov 2015; 14: 165.
5. Botchkina G. Colon cancer stem cells- From basic to clinical application. Cancer Lett 2013; 338: 127-140.
6. Todaro M, FrancipaneMG, Medema JP et al. Colon cancer stem cells: Promise of targeted therapy. Gastroenterology 2010; 138: 2151-2162.
7. Takebe N, Harris PJ, Warren RQ et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
8. Lu J, Ye X, Fan F et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 2013; 23: 171-185.
9. Das I, Craig C, Funahashi Y et al. Notch oncoproteins depend on gamma-secretase/presenilin activity for processing and function. J Biol Chem 2004; 279: 30771-30780.
10. MummJS, Kopan R. Notch signaling: From the outside in. Dev Biol 2000; 228: 151-165.
11. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998; 393: 382-386.
12. MummJS, Schroeter EH, SaxenaMTet al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 2000; 5: 197-206.
13. Gooz M. ADAM-17: The enzyme that does it all. Crit Rev Biochem Mol Biol 2010; 45: 146-169.
14. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 2009; 15: 2319-2335.
15. Merchant NB, Voskresensky I, RogersCM et al. TACE/ADAM-17: A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008; 14: 1182-1191.
16. Richards FM, Tape CJ, Jodrell DI et al. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One 2012; 7: e40597.
17. Van Schaeybroeck S, Kyula JN, Fenton A et al. Oncogenic Kras promotes chemotherapyinduced growth factor shedding via ADAM17. Cancer Res 2011; 71: 1071-1080.
18. Baumgart A, Seidl S, Vlachou P et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res 2010; 70: 5368-5378.
19. McGowan PM, Ryan BM, Hill AD et al. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 2007; 13: 2335-2343.
20. Zhou BB, Peyton M, He B et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50.
21. Kamarajan P, Shin JM, Qian X et al. ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC. CancerMed2013; 2: 793-802.
22. Chen X, Chen L, Zhang R et al. ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells. Neurosci Lett 2013; 537: 44-49.
23. Wang R, Kwon IK, Singh N et al. Type 2 cGMP-dependent protein kinase regulates homeostasis by blocking c-Jun N-terminal kinase in the colon epithelium. Cell Death Differ 2014; 21: 427-437.
24. Reynolds BA, TetzlaffW, Weiss S. Amultipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 1992; 12: 4565-4574.
25. Gamelin E, Delva R, Jacob J et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2099- 2105.
26. Vidal SJ, Rodriguez-Bravo V, Galsky M et al. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014; 33: 4451-4463.
27. Fan F, Bellister S, Lu J et al. The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. Br J Cancer 2015; 112: 539-546.
28. Medema JP. Cancer stem cells: The challenges ahead. Nat Cell Biol 2013; 15: 338-344.
29. Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
30. Yu CC, Tsai LL, Wang ML et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013; 73: 3425-3440.
31. Yang J, Liao D, Chen C et al. Tumorassociated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. STEM CELLS 2013; 31: 248-258.
32. Caiazza F, McGowan PM, Mullooly M et al. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer 2015; 112: 1895-1903.
33. Huang Y, Benaich N, Tape C et al. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. Int J Biol Sci 2014; 10: 702-714.
34. McGowan PM, Mullooly M, Caiazza F et al. ADAM-17: A novel therapeutic target for triple negative breast cancer. Ann Oncol 2013; 24: 362-369.
35. Kyula JN, Van Schaeybroeck S, Doherty J et al. Chemotherapy-induced activation of ADAM-17: Anovelmechanismof drug resistance in colorectal cancer. Clin Cancer Res 2010; 16: 3378-3389.
36. Effenberger T, von der Heyde J, Bartsch K et al. Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. FASEB J 2014; 28: 4847-4856.
37. Sukor S, McGowan PM, MulloolyMet al. ADAM17as a novel therapeutic target for HER2- positive breast cancer. J Clin Oncol 2012; 30 (suppl): 622a.
38. Rios-Doria J, Sabol D, Chesebrough J et al. A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR mediated pathways. Mol Cancer Ther 2015; 14: 1637-1649.
39. Bray SJ. Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689.
40. Sun D, Li H, Zolkiewska A. The role of Delta-like 1 shedding in muscle cell selfrenewal and differentiation. J Cell Sci 2008; 121: 3815-3823.
41. Muraguchi T, Takegami Y, Ohtsuka T et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat Neurosci 2007; 10: 838-845.